Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on clinical data releases, financial results, and material corporate agreements for this commercial-stage biopharmaceutical company focused on targeted cancer therapies.
Day One uses Form 8-K to report material events such as updated three-year data from the pivotal FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma, financial results for specific quarters, and changes to corporate presentations. For example, an 8-K dated November 24, 2025 describes FIREFLY-1 efficacy and safety outcomes, while other 8-Ks attach press releases and slide decks summarizing OJEMDA net product revenue, license revenue, operating expenses, and cash balances.
Filings also document transactional and corporate actions. An 8-K filed in November 2025 outlines the Agreement and Plan of Merger through which Day One agreed to acquire Mersana Therapeutics via a tender offer and subsequent merger, including the structure of cash consideration and contingent value rights. Another 8-K describes an option repricing approved by the board of directors, providing detail on how stock options for certain directors and employees are adjusted and conditioned on continued service.
Through these SEC documents, readers can examine how Day One reports clinical trial outcomes, such as response rates and treatment-free intervals from FIREFLY-1, as well as how it communicates financial performance and corporate governance decisions. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight key points, helping users quickly understand the context of each report while preserving access to the full underlying documents.
In addition to 8-Ks, investors may use this page as a starting point to locate Day One’s annual and quarterly reports, which provide broader overviews of its oncology pipeline, including OJEMDA, DAY301, and Emi-Le, and its status as a Nasdaq Global Select Market registrant under the symbol DAWN.
Day One Biopharmaceuticals (DAWN) filed a Form 4 showing an option repricing for a director. On 11/06/2025, fully vested stock options were repriced to an exercise price of $8.99, replacing prior grants with higher strike prices while keeping original terms and expirations. The transactions include exchanges of 63,000 (from $16; expiring 05/25/2031), 1,181 (from $16; 05/25/2031), 28,700 (from $16.29; 06/20/2032), 37,500 (from $12.69; 06/21/2033), and 32,335 (from $13.87; 05/22/2034) options, each reacquired at $8.99. The board approved the repricing on 10/07/2025. Exercising at the new price requires service through a “Retention Period” that ends on the earliest of the 12‑month anniversary of the effective date or a Corporate Transaction; other terms remain unchanged.
Day One Biopharmaceuticals (DAWN) disclosed a director’s option repricing on a Form 4. The Board approved the action on October 7, 2025, and it became effective on November 6, 2025. Previously granted stock options with exercise prices of $16.00, $16.29, $12.69, and $13.87 were disposed and replaced with options at a new exercise price of $8.99.
The repriced grants cover 40,000, 40,300, 28,700, 37,500, and 32,335 underlying shares, respectively, and are reported as directly owned. The options are fully vested. To exercise at the new price, the reporting person must remain in service through the “Retention Period,” which ends at the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction; the footnotes note an exception related to death or Disability under the company’s 2021 Equity Incentive Plan. The transactions were exempt under Rules 16b‑6(d) and 16b‑3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 reporting an option repricing for a director. On 11/06/2025, previously granted stock options with exercise prices of $25.84 (33,900 shares), $12.69 (37,500 shares), and $13.87 (32,335 shares) were replaced with options at a new exercise price of $8.99, matching the Nasdaq closing price on the effective date. The Board approved the repricing on 10/07/2025.
The options are fully vested. To exercise at the new price, the reporting person must remain in service through the “Retention Period,” which ends at the earlier of the 12-month anniversary of 11/06/2025 or a Corporate Transaction, with certain exceptions for death or Disability as defined in the company’s 2021 plan.
Day One Biopharmaceuticals (DAWN) director filed a Form 4 reporting an option repricing approved on Oct 7, 2025 and effective Nov 6, 2025. The exercise price for certain fully vested stock options was reset to $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover 48,072 options (from $24.65; expiring Aug 15, 2031), 28,700 (from $16.29; expiring Jun 20, 2032), 37,500 (from $12.69; expiring Jun 21, 2033), and 32,335 (from $13.87; expiring May 22, 2034). All other terms remain unchanged.
Exercising at the new price requires service through the Retention Period, which runs from Nov 6, 2025 until the earlier of the 12-month anniversary or a Corporate Transaction, with specified exceptions for death or Disability.
Day One Biopharmaceuticals (DAWN): Form 4 discloses option repricing by a director. On 11/06/2025, previously granted and fully vested stock options with exercise prices ranging from $12.69 to $16.29 were canceled and replaced at a new exercise price of $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover multiple tranches with original expirations unchanged (ranging from 05/25/2031 to 05/22/2034). Exercising at the new price requires service through the “Retention Period,” which ends on the earlier of 12 months from the effective date or a Corporate Transaction, with specified exceptions. The transactions were exempt under Rule 16b-6(d) and Rule 16b-3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 showing an option repricing for its COO and CFO. On November 6, 2025, multiple stock option grants held by the reporting person were repriced to an exercise price of $8.99 if lower than the original price, following a Board approval on October 7, 2025.
The filing lists prior grants adjusted from higher strikes, including 497,667 underlying shares previously at $16 (fully vested), 151,000 at $14.26, 116,000 at $23.41, 162,000 at $14.44, and 162,000 at $11.87. The revised entries show corresponding grants at $8.99 with the same underlying share counts. Vesting terms remain unchanged, such as 2.0833% monthly with full vest by January 18, 2026, and multiple 1/48th monthly schedules starting on specified dates.
To exercise at the new price, continued service is required through the “Retention Period,” which runs from the effective date until the earlier of 12 months or a Corporate Transaction, with an exception for death or Disability under the plan.
Day One Biopharmaceuticals (DAWN) filed a Form 4 for its General Counsel & Secretary. On 11/06/2025, the officer was granted a stock option for 309,000 shares at an exercise price of $8.99, vesting 100% on November 6, 2026.
The filing also records an option repricing approved on October 7, 2025 and effective November 6, 2025: three existing options covering 90,000 shares each were canceled at prior exercise prices of $23.41, $14.44, and $11.87 and replaced with options at $8.99, keeping original expirations in 2033–2035 and monthly vesting schedules. To exercise at the new price, service through the Retention Period is required, which ends at the earlier of the 12‑month anniversary of the Effective Date or a Corporate Transaction.
Day One Biopharmaceuticals (DAWN) reported a director’s Form 4 reflecting an option repricing effective November 6, 2025. Existing stock options were reset to a new exercise price of $8.99, the Nasdaq closing price on the effective date.
The filing shows dispositions of options previously priced at $13.81 (66,660 shares; expiring 01/16/2034) and $13.87 (32,335 shares; expiring 05/22/2034), and corresponding acquisitions of options for the same share amounts at $8.99 with the same expiration dates. One grant vests 1/36 monthly beginning February 17, 2024; the other is fully vested. Exercising at the new price requires continued service through a defined Retention Period, and the transactions were noted as exempt under Rule 16b-6(d) and Rule 16b-3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 reporting an option repricing for its Chief Commercial Officer. On November 6, 2025, certain stock options were repriced to a new exercise price of $8.99, equal to the Nasdaq closing price on the effective date.
The transactions replaced prior exercise prices for options covering 330,200 shares (originally $12.54, expiring 06/11/2033), 90,000 shares (originally $14.44, expiring 01/04/2034), and 90,000 shares (originally $11.87, expiring 01/14/2035). All other terms remain unchanged. To exercise at $8.99, the reporting person must remain in service through the Retention Period, which ends on the earliest of the 12‑month anniversary of the effective date or a Corporate Transaction; the additional premium is waived upon death or disability.
Vesting continues as previously set: 25% on June 12, 2024 with monthly vesting thereafter through June 12, 2027 for the 330,200‑share grant; and 1/48th monthly starting February 5, 2024 and February 15, 2025 for the two 90,000‑share grants. The issuer states these transactions are exempt under Rule 16b‑6(d) and Rule 16b‑3.
Day One Biopharmaceuticals (DAWN) filed its Q3 2025 10‑Q, showing continued commercial ramp of OJEMDA. Total revenue was $39.8 million, driven by product revenue of $38.5 million (vs. $20.1 million in Q3 2024). The company reported a net loss of $19.7 million (vs. net income of $37.0 million last year, which included significant license revenue).
Year to date, revenue totaled $104.5 million with $102.6 million from product sales. Operating expenses were $64.0 million in Q3, including R&D of $31.4 million and SG&A of $28.1 million. Cash and cash equivalents were $43.3 million and short‑term investments $408.3 million, for total assets of $513.8 million and stockholders’ equity of $450.9 million as of September 30, 2025.
Customer concentration remains high: two customers accounted for 98.6% of Q3 net product revenue. The Ipsen out‑licensing continues to be recognized over time, with $1.3 million of license revenue in Q3 and deferred revenue of $2.3 million current and $3.0 million long‑term. Shares outstanding were 102,675,502 as of October 31, 2025.